<DOC>
	<DOCNO>NCT01660776</DOCNO>
	<brief_summary>Diffuse large B-cell lymphoma ( DLBCLs ) represent 25 30 % adult non-Hodgkin lymphoma western country . DLBCLs aggressive cancer potentially curable multi-agent chemotherapy . Whereas R-CHOP regimen lead marked improvement survival , disease remain biologically heterogeneous entity . New therapeutic strategy require include identification patient ' subgroup different prognostic . This project base BMS_LyTrans Goelams 075 clinical trial . A study whole blood transcriptome 75 DLBCL patient 87 control show PD-L1 ( CD274 ) gene overexpressed DLBCL patient . Preliminary result demonstrate PD-L1 detect plasma DLBCL patient significantly high concentration control . This protein select potential biomarker establish role anti-tumoral immunity . Interaction PD-L1 receptor PD-1 know inhibit activation immune response induce T-lymphocytes anergy and/or apoptosis . Moreover , direct involvement PD-L1 protection cancer cell lysis activate T lymphocyte demonstrate . PD-L1 expression describe several solid tumour , include ovary cancer , breast cancer , colon cancer , renal cell carcinoma , non-small cell lung carcinoma hematological malignancy T-NHL , MM Hodgkin 's lymphoma . Furthermore expression PD-L1 tumour cell associate poor prognosis . The blockade PD-L1/PD-1 axis may represent novel therapeutic approach aggressive cancer . These first result incite identify cell release soluble PD-L1 investigate role anti-tumoral immunity DLBCL patient . The aim study identify cell produce soluble PD-L1 DLBCL patient diagnosis comparison others tumours know express PD-L1 ( metastatic breast cancer , Hodgkin 's lymphoma , non-small cell lung cancer ) .</brief_summary>
	<brief_title>BMS_PD-L1_onco : Assessment PD-L1 Protein Biomarker Oncology Hematology</brief_title>
	<detailed_description>Secondary purpose : - To confirm presence plasma soluble form PD-L1 others malignancies - To study surface expression PD-L1 circulate tumour cell multiparameter fow cytometry Veridex® technology DLBCL metastatic breast cancer patient - To study surface expression PD-L1 circulate endothelial cell DLBCL , Hodgkin lymphoma metastatic breast cancer patient ( subpart end late 2012 ) - To study surface expression PD-L1 different type leukocyte ( monocyte , B T lymphocytes ) - To separate circulate tumour cell express PD-L1 immunomagnetic Cell-sorting method - To develop ELISPOT technique study release soluble PD-L1 culture supernatant select cell ( subpart end mid 2013 ) - evaluate correlation expression PD-L1 plasma * ) expression PD-L1 tumor , ** ) expression PD-L1 molecule bronchoalveolar liquid ( whenever available routine ) non-small cell lung cancer - evaluate response treatment accord plasma PD-L1 expression non-small cell lung cancer - evaluate susceptibility develop disease accord single nucleotide polymorphism PD-L1 gene DLBCL non-small cell lung cancer - Constitution different cohort collection sample Main cohort : de novo DLBCL diagnosis Secondary cohort : Hodgkin 's lymphoma , metastatic breast cancer , non small cell lung cancer Control cohorts : healthy volunteer ( blood donor ) , patient immune thrombocytopenia ( ITP ) - Quantification plasma soluble PD-L1 different cohort</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>General inclusion criterion : Age ≥ 18 year ≤ 75 year , Life expectancy 4 month Signed informed consent obtain Social security affiliation mandatory Non previously treat ( even corticotherapy ) , HIV negative , HBs negative , HCV negative Inclusion criterion DLBCL patient : A biopsy proven diagnosis de novo DLBCL accord current WHO criterion , Immunohistochemistry GCB/nonGC classification accord Hans ' algorithm Patients advancedstage disease define Ann Arbor stage III IV , stag I II bulky disease ( &gt; 7cm ) Inclusion criterion nonsmall cell lung cancer patient : A biopsy proven diagnosis de novo nonsmall cell lung cancer ( stage ) accord current WHO criteria Inclusion criterion Hodgkin 's lymphoma patient : A biopsy proven diagnosis Hodgkin 's lymphoma accord current WHO criteria Inclusion criterion metastatic breast cancer lymph node involvement : A biopsy proven diagnosis infiltrate lobular ductal breast carcinoma lymph node involvement metastasis Inclusion criterion patient immune thrombocytopenia ( ITP ) : Primary ITP define IWG platelet count le 100 G/L absence cause disorder may associate thrombocytopenia . Bone marrow examination exclude central aetiology thrombocytopenia Inclusion criterion healthy volunteer : Inclusion criterion blood donation accord Etablissement Français du Sang ( EFS ) criteria General noninclusion criterion : Age &lt; 18 year et &gt; 75 year , Pregnant woman , Person legally involve case No social security affiliation Signed informed consent obtain , Preliminary treatment ( even corticoid treatment ) . HIV positive , HBs positive , HCV positive Noninclusion criterion DLBCL patient : Lymphoma DLBCL , Transformation low grade lymphoma high grade lymphoma ( DLBCL ) , Extranodal marginal zone lymphoma MALT lymphoma , Posttransplant lymphoproliferative disorder , Lymphoblastic lymphoma , Burkitt 's lymphoma , Carcinoma history carcinoma except situ cervical carcinoma . Noninclusion criterion nonsmall cell lung cancer patient : None Noninclusion criterion Hodgkin patient : Non Hodgkin 's lymphoma Noninclusion criterion metastatic breast cancer lymph node involvement : Carcinoma infiltrate lobular ductal breast carcinoma Chemotherapy 30 day precede inclusion Hormonotherapy 7 day precede inclusion Carcinoma history carcinoma except situ cervical carcinoma . Hemoglobin level &lt; 10g/dl Noninclusion criterion patient immune thrombocytopenia ( ITP ) : Central aetiology thrombocytopenia Noninclusion criterion healthy volunteer : Exclusion criterion blood donation accord Etablissement Français du Sang ( EFS ) criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diffuse large B-cell lymphoma ( DLBCL )</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>metastatic breast cancer .</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>